APA (7th ed.) Citation

YH, K., CY, C., MR, C., D, C., U, F., T, F., . . . C, T. (2026). Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial. Annals of hematology, 105(3), 79. https://doi.org/10.1007/s00277-026-06798-4

Chicago Style (17th ed.) Citation

YH, Karimi, et al. "Efficacy and Safety of Epcoritamab in Relapsed or Refractory Large B-cell Lymphoma: 3-year Update from the EPCORE NHL-1 Trial." Annals of Hematology 105, no. 3 (2026): 79. https://doi.org/10.1007/s00277-026-06798-4.

MLA (9th ed.) Citation

YH, Karimi, et al. "Efficacy and Safety of Epcoritamab in Relapsed or Refractory Large B-cell Lymphoma: 3-year Update from the EPCORE NHL-1 Trial." Annals of Hematology, vol. 105, no. 3, 2026, p. 79, https://doi.org/10.1007/s00277-026-06798-4.